Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT04670887

Comparison of Surgery and Active Surveillance in the Treatment of Bosniak III Renal Cysts

The incidence of renal cysts is rising due to increased abdominal imaging. Renal complicated cysts have been traditionally classified according to the Bosniak classification, which distinguishes cystic masses by specific features of walls and septa. The categories I and II are benign and class IIF most probably benign but needs a short radiological follow-up. Categories III and IV have been traditionally operated due to the increased risk of renal cell carcinoma. However, recently published studies show that approximately 50% of the operated Bosniak III cystic masses are benign, which means that half of the cases are overtreated by surgery. It has also been shown that surgical pathology of stable Bosniak IIF cysts is malignant in less than 1%, while the cysts, which are upgraded to higher Bosniak classes will show malignant surgical pathology in 85%. So far, there is lack of prospective data on active surveillance in Bosniak III cystic masses.

The aim of the study is to compare active surveillance and surgery in patients with Bosniak III renal cystic masses. Patients will be randomized in active surveillance or immediate surgical excision of a cystic mass. In the active surveillance group, patients are followed according to the study protocol for 10 years and treated with delayed surgery if the cystic mass upgrades into Bosniak IV/solid, becomes symptomatic or grows over a preclassified threshold. The primary objective is to compare surgical pathology between patients treated with immediate surgery versus delayed surgery.

According to recent retrospective data, active surveillance of Bosniak III cystic masses is reasonable and oncologically safe. Therefore a prospective randomized controlled trial is needed to get high level evidence to support a change in the treatment strategy. The study may significantly reduce unnecessary operations performed in patients with Bosniak III cystic masses.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A sporadic single CM of Bosniak 3 according to the Bosniak Classification v.2019 is diagnosed with CT or MRI
  • Maximal diameter of CM 10-70 mm
  • Age ≥50 years
  • ECOG performance status <2
  • Life expectancy ≥5 years
  • Patient is fit to undergo surgery and AS.
  • Patient understands a national language or English
  • Signed informed consent

Exclusion criteria

  • Genetic syndromes associated with RCC
  • Previously or simultaneously diagnosed and pathologically verified RCC
  • Previously or simultaneously radiographically identified solid mass or CM of Bosniak 3/4 with diameter ≥10mm
  • The target CM of Bosniak 3 has progressed in sequential imaging from Bosniak 1-2F
  • Presence of radiographic findings which are suspect for nodal or distant metastatic disease
  • Symptomatic CM
  • Kidney insufficiency (GFR<55 ml/min/1,73m2)
  • Patients who have contraindications for both CT and MRI imaging. . Anatomically solitary kidney

Treatment and study plan

Delayed surgery

Procedure

Delayed surgery is performed if cystic mass radiologically upgrades into Bosniak 4 or solid mass in the active surveillance.

Immediate surgery

Procedure

Partial or radical nephrectomy is performed as treatment of Bosniak 3 cystic mass

Primary outcomes

  1. Malignancy rate in surgical pathology

    Time frame: From date of randomization until the date of surgery, assessed up to 120 months

Secondary outcomes

  1. Cancer specific survival

    Time frame: From date of randomization until the date of death due to renal cancer, assessed up to 120 months

  2. Progression-free survival

    Time frame: From date of randomization until the date of first documented progression, assessed up to 120 months

  3. Overall survival

    Time frame: From date of randomization until the date of death from any cause, assessed up to 120 months

Study contacts

Contact information is provided by the study sponsor or research team.

Harry Nisén, Adj. professor

CONTACT

[email protected]

+35894711

Juhana Rautiola

CONTACT

[email protected]

+35894711

Sponsors and collaborators

Lead sponsor

Helsinki University Central Hospital

Other

Registry information

Official study title

A Prospective Multicenter Trial Comparing Surgery Versus Active Surveillance In Patients With Bosniak 3 Renal Cystic Masses, A NoRenCa And FinnKidney Study

Important dates

Study start
2021
Primary completion
2024
Study completion
2036
First posted
Dec 17, 2020
Registry last updated
Feb 17, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.